Meeting
2019 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
Authors
Laura Spring
Massachusetts General Hospital Cancer Center, Boston, MA
Laura Spring , Shom Goel , Sara Sutherland , Jeffrey G. Supko , Dejan Juric , Steven J. Isakoff , Erica L. Mayer , Beverly Moy , Sara M. Tolaney , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02657343
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1028)
DOI
10.1200/JCO.2019.37.15_suppl.1028
Abstract #
1028
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.
First Author: Laura Spring
Poster
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
First Author: Jian Zhang
Poster
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
First Author: Patricia Villagrasa